IDEXX Laboratories reported second-quarter revenue of $1.109 billion, an 11% increase year-on-year, comfortably ahead of analyst expectations. Diluted earnings per share climbed 49% to $3.63, also topping forecasts. Gross margin widened to 62.6% while operating margin reached 33.6%, supported by record placements of roughly 2,400 inVue Dx analyzers and double-digit growth in VetLab consumables. Companion-animal diagnostics recurring revenue advanced 9% as reported and 7% on an organic basis, with international markets growing faster than the United States. Net income rose to $294 million from $203 million a year earlier despite continued softness in veterinary clinic visit volumes. Management lifted full-year 2025 guidance, projecting revenue of $4.205 billion to $4.28 billion, up about $90 million at the midpoint, and raising the EPS range to $12.40–$12.76. The company now targets 7–9% organic revenue growth and expects operating margins of 31.3–31.6%. Investors welcomed the outlook upgrade; IDEXX shares surged roughly 25–27% in pre-market and early regular trading on 4 August, extending a rally that began after the company previewed solid instrument demand last week.